Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical has reported encouraging interim data from its ongoing phase Ib/II study of arfolitixorin in RAS-mutated metastatic colorectal cancer, an especially hard-to-treat patient group. Conducted initially at Charité – Universitätsmedizin Berlin, the trial is testing an optimized dosing regimen and is now assessing a third dose level of 300 mg/m2, with plans to expand to additional hospitals and a broader phase II cohort including a control arm.
All patients evaluated so far have shown tumor shrinkage without dose-limiting side effects, with reductions in total tumor burden of up to about 50 percent. Notably, half of the six patients assessed have responded so strongly that they were taken off study to be considered for tumor surgery, a rare possibility in this population, underscoring the potential of arfolitixorin to address a major treatment gap in colorectal cancer, the world’s third most common malignancy and a leading cause of cancer death.
Investigators and company management describe the results as unexpectedly positive, highlighting both the apparent safety and the early efficacy signal from the new dosing strategy. Isofol plans to present additional data from the trial at medical conferences later in the year, a development that could influence its clinical strategy and strengthen its positioning in the competitive oncology drug-development landscape.
The most recent analyst rating on (SE:ISOFOL) stock is a Sell with a SEK0.56 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
More about Isofol Medical AB
Isofol Medical AB is a Swedish biotechnology company focused on improving treatment outcomes and quality of life for patients with severe cancers. Its lead clinical asset, arfolitixorin, is a proprietary folate-based drug candidate intended to boost the efficacy of first-line standard therapies for solid tumors, currently being evaluated in colorectal cancer. The company is listed on Nasdaq Stockholm and operates from Gothenburg with a focus on high-need oncology indications.
Average Trading Volume: 447,179
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK165.4M
Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.